This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KERX at https://www.zacks.com/ap/KERX Keywords: Keryx …
Keryx Biopharmaceuticals, Inc. KERX is expected to report second-quarter 2016 results on Aug 3. Keryx’s track record has been disappointing so far. Over the four trailing quarters, the company posted an average negative earnings surprise …
Keryx Biopharmaceuticals (NASDAQ:KERX - News ... report or letter, PropThink, LLC and persons or entities with whom it has relationships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) …
SmarTrend identified a Downtrend for Keryx Biopharm (NASDAQ:KERX) on October 18th, 2017 at $6.64. In approximately 3 months, Keryx Biopharm has returned 23.19% as of today's recent price of $5.10. Over the past year, Keryx …
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in …
More from The Tell. Must be lonely being a bear these days. Faber took a more traditional tack when he used the Greek stock market’s rally to support the time-tested axiom: “So you need to buy stocks when there’s no reason to buy them …
The stock recorded a trading volume of 1.87 million shares. The Company's shares have gained 13.89% over the last …
The stock recorded a trading volume of 1.87 million shares. The Company's shares have gained 13.89% over the last …
WBOC3mon
Analyst’s mean target price for DO is $14.79 while analysts mean recommendation is 3.50. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)’s stock on Tuesday traded at beginning with a price of $ 4.49 and when day-trade ended the …